Industry updates with Dusko Ilic: June 2026

Written by Dusko ILIC
CAR-T Cell therapy Clinical manufacturing Clinical trials FDA Gene therapy Industry developments iPSCs Manufacturing & scale-up Opinion Regulation & policy Report Stem cells

Every month, Dusko Ilic (King's College London; UK) explores the latest breakthroughs and trends shaping the field in his Industry Updates article for our sister journal Regenerative Medicine. Here, he answers three quick-fire questions about the key insights: what did he expect, what surprised him, and what’s the one story we shouldn’t miss? What happened this month that you were expecting? In vivo CRISPR grows up One development I was expecting this month was continued late-stage progress for in vivo CRISPR medicines. Intellia Therapeutics (MA, USA) reported additional positive Phase III data for lonvoguran ziclumeran, or lonvo-z, its single-dose in vivo...

To view this content, please register now for access

It's completely free